DF
MCID: DNG005
MIFTS: 57

Dengue Virus (DF)

Categories: Blood diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases

Aliases & Classifications for Dengue Virus

MalaCards integrated aliases for Dengue Virus:

Name: Dengue Virus 56
Dengue Fever, Protection Against 56 13 6
Dengue Virus, Susceptibility to 56 29 39
Dengue Fever 58 3 71
Df 58 3
Dengue Virus Infection 58

Characteristics:

Orphanet epidemiological data:

58
dengue fever
Prevalence: >1/1000 (Worldwide),1-9/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 58  
Rare infectious diseases


Summaries for Dengue Virus

OMIM : 56 Dengue virus is a flavivirus belonging to the family Flaviviridae. Its principal vector is Aedes aegypti, a highly urbanized, daytime-biting mosquito that breeds in stored water. There are 4 antigenetically variant serotypes of dengue virus, DEN-1 to DEN-4, and type-specific immunity against one serotype cannot block infection with another serotype. Disease manifestations following dengue infection range from subclinical infection to severe and fatal disease, with age, gender, genotype, immunologic status, and flavivirus infection history of the host all influencing disease severity. Primary infection is mainly associated with dengue fever (DF). Symptoms of DF typically appear 4 to 7 days after the mosquito bite and include high fever, headache, retroocular pain, conjunctival changes, and facial flushing. Although primary dengue infections are mostly recovered, a secondary infection with a different serotype of the virus leads to the complex condition of dengue hemorrhagic fever (DHF) with plasma leakage and thrombocytopenia or a more fatal condition, dengue shock syndrome (DSS). High fever, hemorrhagic phenomenon, hepatomegaly, and circulatory failure are mainly associated with DHF. Hemorrhages in DHF are seen in skin, subcutaneous tissues, heart, liver, and gastrointestinal tract. An estimated 50 to 100 million illnesses due to dengue infection occur annually, including 250,000 to 500,000 cases of DHF and 24,000 deaths. About 2.5 billion people are estimated to be at risk, particularly those living in tropical and subtropical areas of Asia and Latin America (reviews by Faheem et al. (2011), Whitehorn and Simmons (2011), and Guzman et al. (2010)). (614371)

MalaCards based summary : Dengue Virus, also known as dengue fever, protection against, is related to encephalitis and viral infectious disease, and has symptoms including fever and pruritus. An important gene associated with Dengue Virus is CD209 (CD209 Molecule), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Histamine and Ketotifen have been mentioned in the context of this disorder. Affiliated tissues include t cells, testes and endothelial, and related phenotypes are fever and headache

CDC : 3 Dengue viruses are spread to people through the bite of an infected Aedes species (Ae. aegypti or Ae. albopictus) mosquito. Dengue is common in more than 100 countries around the world. Forty percent of the world's population, about 3 billion people, live in areas with a risk of dengue. Dengue is often a leading cause of illness in areas with risk.

Wikipedia : 74 Dengue virus (DENV) is the cause of dengue fever. It is a mosquito-borne, single positive-stranded RNA... more...

Related Diseases for Dengue Virus

Diseases in the Dengue Virus family:

Dengue Disease

Diseases related to Dengue Virus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 465)
# Related Disease Score Top Affiliating Genes
1 encephalitis 30.9 RSAD2 RPSA DDX58 CD209
2 viral infectious disease 30.6 STAT2 IFIH1 DDX58 CD209
3 chikungunya 30.5 SHFL RSAD2 OAS3 DDX58 CD209
4 west nile virus 30.4 RSAD2 IFITM3 IFITM2 IFITM1 IFIH1 EXOC1
5 west nile fever 30.0 OAS3 CD209
6 tick-borne encephalitis 30.0 RSAD2 OAS3 DDX58 CD209
7 measles 29.9 STAT2 IFIH1 DDX58 CD209
8 lassa fever 29.8 IFIH1 DDX58 CD209
9 stomatitis 29.7 RSAD2 IFITM3 IFITM2 DDX58
10 rift valley fever 29.6 IFITM3 IFITM2 IFITM1 CD209
11 hepatitis c virus 29.0 RSAD2 IFITM1 IFIH1 DDX58 CLDN1
12 hepatitis 28.4 RSAD2 MRC1 IFIH1 HAVCR1 DDX58 CLDN1
13 influenza 28.2 RSAD2 IFITM3 IFITM2 IFITM1 IFIH1 DDX58
14 dengue disease 12.5
15 dengue shock syndrome 11.9
16 dengue hemorrhagic fever 11.9
17 asymptomatic dengue 11.8
18 kyasanur forest disease 11.3
19 yellow fever 10.8
20 japanese encephalitis 10.8
21 thrombocytopenia 10.7
22 exanthem 10.6
23 cytokine deficiency 10.6
24 vaccinia 10.5
25 zika fever 10.4
26 severe combined immunodeficiency 10.4
27 microcephaly 10.4
28 neutropenia 10.4
29 guillain-barre syndrome 10.4
30 appendicitis 10.3
31 hemorrhagic disease 10.3
32 48,xyyy 10.3
33 st. louis encephalitis 10.3
34 form agnosia 10.3
35 agnosia 10.3
36 viral hemorrhagic fever 10.3
37 viral hepatitis 10.2
38 acute pancreatitis 10.2
39 myelitis 10.2
40 myositis 10.2
41 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.2
42 viral encephalitis 10.2
43 neuroblastoma 10.2
44 acute liver failure 10.2
45 kawasaki disease 10.2
46 acute kidney tubular necrosis 10.2
47 uveitis 10.2
48 dermatitis, atopic 10.2
49 rhinitis 10.2
50 polykaryocytosis inducer 10.2

Graphical network of the top 20 diseases related to Dengue Virus:



Diseases related to Dengue Virus

Symptoms & Phenotypes for Dengue Virus

Human phenotypes related to Dengue Virus:

58 31 (show all 22)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 58 31 hallmark (90%) Very frequent (99-80%) HP:0001945
2 headache 58 31 hallmark (90%) Very frequent (99-80%) HP:0002315
3 arthralgia 58 31 frequent (33%) Frequent (79-30%) HP:0002829
4 abdominal pain 58 31 frequent (33%) Frequent (79-30%) HP:0002027
5 pruritus 58 31 frequent (33%) Frequent (79-30%) HP:0000989
6 skin rash 58 31 frequent (33%) Frequent (79-30%) HP:0000988
7 nausea and vomiting 58 31 occasional (7.5%) Occasional (29-5%) HP:0002017
8 hypotension 58 31 occasional (7.5%) Occasional (29-5%) HP:0002615
9 hepatomegaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0002240
10 ascites 58 31 occasional (7.5%) Occasional (29-5%) HP:0001541
11 gingival bleeding 58 31 occasional (7.5%) Occasional (29-5%) HP:0000225
12 gastrointestinal hemorrhage 58 31 occasional (7.5%) Occasional (29-5%) HP:0002239
13 thrombocytopenia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001873
14 diarrhea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002014
15 epistaxis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000421
16 bruising susceptibility 58 31 occasional (7.5%) Occasional (29-5%) HP:0000978
17 petechiae 58 31 occasional (7.5%) Occasional (29-5%) HP:0000967
18 lethargy 58 31 occasional (7.5%) Occasional (29-5%) HP:0001254
19 cerebral hemorrhage 58 31 occasional (7.5%) Occasional (29-5%) HP:0001342
20 leukopenia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001882
21 hypoproteinemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003075
22 cardiorespiratory arrest 58 31 occasional (7.5%) Occasional (29-5%) HP:0006543

Clinical features from OMIM:

614371

UMLS symptoms related to Dengue Virus:


fever, pruritus

Drugs & Therapeutics for Dengue Virus

Drugs for Dengue Virus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 39)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4 51-45-6 774
2
Ketotifen Approved Phase 4 34580-13-7, 34580-14-8 3827
3 Neurotransmitter Agents Phase 4
4 Histamine H1 Antagonists Phase 4
5 Dermatologic Agents Phase 4
6
Histamine Phosphate Phase 4 51-74-1 65513
7 Antipruritics Phase 4
8 Histamine Antagonists Phase 4
9 Anti-Allergic Agents Phase 4
10
tannic acid Approved Phase 3 1401-55-4
11
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
12 Antiparasitic Agents Phase 2, Phase 3
13 Anti-Infective Agents Phase 2, Phase 3
14 Heptavalent Pneumococcal Conjugate Vaccine Phase 3
15 Immunologic Factors Phase 3
16 Immunoglobulins Phase 3
17 Antibodies Phase 3
18
Neomycin Approved, Vet_approved Phase 1, Phase 2 1404-04-2 8378
19 Pharmaceutical Solutions Phase 2
20 Rho(D) Immune Globulin Phase 2
21 Immunoglobulins, Intravenous Phase 2
22 gamma-Globulins Phase 2
23 Plasma-lyte 148 Phase 2
24
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
25
Aluminum sulfate Approved Phase 1 10043-01-3
26
Varespladib methyl Investigational Phase 1 172733-08-3
27 Vaccines Phase 1
28 Gastrointestinal Agents Phase 1
29 Adjuvants, Immunologic Phase 1
30 Anti-Ulcer Agents Phase 1
31 Antacids Phase 1
32
Ivermectin Approved, Investigational, Vet_approved 70288-86-7 6474909
33
Mebendazole Approved, Vet_approved 31431-39-7 4030
34
Albendazole Approved, Vet_approved 54965-21-8 2082
35
Caffeine Approved 58-08-2 2519
36 Nonoxynol
37 Contraceptive Agents
38 Contraceptive Agents, Male
39 Spermatocidal Agents

Interventional clinical trials:

(show top 50) (show all 149)
# Name Status NCT ID Phase Drugs
1 Ketotifen as a Treatment for Vascular Leakage During Dengue Fever (KETODEN) Unknown status NCT02673840 Phase 4 Ketotifen;Placebo
2 A Phase II/III, Randomized, Placebo Controlled Trial of Efficacy and Safety of Ivermectin in Children and Adult Patients With Dengue Infection Unknown status NCT02045069 Phase 2, Phase 3 2 days Ivermectin;3 days Ivermectin;Placebo
3 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia Completed NCT01254422 Phase 3
4 Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Completed NCT01374516 Phase 3
5 Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril®) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers at 12-13 Months of Age in Colombia and Peru Completed NCT01436396 Phase 3
6 Lot-to-Lot Consistency and Bridging Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia Completed NCT01134263 Phase 3
7 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® in Healthy Female Subjects Aged 9 to 14 Years in Mexico Completed NCT02979535 Phase 3
8 Immunogenicity and Safety of a Booster Injection of DTaP-IPV//Hib (Pentaxim™) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers Aged 15 to 18 Months in Mexico Completed NCT01411241 Phase 3
9 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Demonstrate Lot-to-Lot Consistency of 3 Lots of a Tetravalent Dengue Vaccine Candidate in Healthy Adults in Non-Endemic Country(Ies) for Dengue Completed NCT03423173 Phase 3
10 Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia Completed NCT01373281 Phase 3
11 Albumin 5% as Resuscitation in Adult Dengue Fever Patients With Plasma Leakage Recruiting NCT04076254 Phase 3 Albumins;Fluid
12 A Phase 3, Follow-Up Trial to Evaluate Long-Term Safety and Antibody Persistence, and the Impact of a Booster Dose of a Tetravalent Dengue Vaccine Candidate in Healthy Adolescents and Adults in Areas Non-Endemic for Dengue Recruiting NCT03999996 Phase 3
13 Phase III, Double-Blind, Randomized, Placebo-Controlled Trial to Investigate the Efficacy, Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TDV) Administered Subcutaneously in Healthy Children Aged 4 - 16 Years Old Active, not recruiting NCT02747927 Phase 3 TDV Placebo
14 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® in Healthy Subjects Aged 9 to 13 Years in Malaysia Active, not recruiting NCT02993757 Phase 3
15 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects Aged 9 to 60 Years in the Philippines Active, not recruiting NCT02992418 Phase 3
16 An Open-Label, Phase 3 Trial to Investigate the Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) at the End of Shelf Life in Healthy Adults in Non-Endemic Country(Ies) for Dengue Active, not recruiting NCT03771963 Phase 3
17 Safety and Immunogenicity of Bivalent and Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Flavivirus-Naïve Adults Aged 18 to 45 Years Completed NCT00740155 Phase 2
18 Immunogenicity and Safety of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Viet Nam Completed NCT00875524 Phase 2
19 Safety of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Previously Immunised With an Investigational Dengue or Yellow Fever Vaccine Completed NCT00730288 Phase 2
20 Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Completed NCT00993447 Phase 2
21 Exploration of Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity Following Various Administration Schedules With CYD Tetravalent Dengue Vaccine Completed NCT01943825 Phase 2
22 Immunogenicity and Safety of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India. Completed NCT01550289 Phase 2
23 Immunogenicity and Safety of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years Previously Vaccinated Against Yellow Fever in Peru Completed NCT00788151 Phase 2
24 Immunogenicity and Large-Scale Safety of Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Singapore Completed NCT00880893 Phase 2
25 Immunogenicity and Safety of Three Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Adults Aged 18 to 45 Years in the US Completed NCT00617344 Phase 2
26 Evaluation of the Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Administered With or Without Yellow Fever Vaccine in US Adults. Completed NCT01488890 Phase 2
27 Phase II, Randomized, Double-blind, Placebo-controlled Study of Two Doses of WRAIR Live Attenuated Tetravalent Dengue Vaccine Formulations, Administered Six Months Apart, to Healthy Adults and Children Completed NCT00468858 Phase 2
28 A Phase II, Double-Blind, Randomized, Controlled Trial to Assess the Safety and Immunogenicity of a Tetravalent Dengue Vaccine With Two Different Serotype 2 Potencies in an Adult Population in Singapore Completed NCT02425098 Phase 2
29 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Singapore Completed NCT02824198 Phase 2
30 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Latin America Completed NCT02623725 Phase 2
31 Efficacy and Safety of Dengue Vaccine in Healthy Children Aged 4 to 11 Years in Thailand Completed NCT00842530 Phase 2
32 Celgosivir Proof of Concept Trial for Treatment of Acute Dengue Fever Completed NCT01619969 Phase 1, Phase 2 celgosivir;placebo
33 A Phase 1/2, Randomized, Observer-blind Study of Varying Injection Schedules of a Tetravalent Dengue Virus Purified Inactivated Vaccine (TDENV-PIV) With AS03B Adjuvant and Placebo in Healthy Adults in the US Completed NCT02421367 Phase 1, Phase 2
34 Immunogenicity and Safety of CYD Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines Completed NCT01064141 Phase 2
35 A Phase II, Double-Blind, Controlled Trial to Assess the Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Subjects Aged Between 2 and <18 Years and Living in Dengue Endemic Countries in Asia and Latin America Completed NCT02302066 Phase 2 TDV Placebo
36 A Double-Blind, Randomized, Placebo-Controlled, Age Descending and Expansion Phase 2 Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years Completed NCT01511250 Phase 2
37 Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Immunogenicity of Two Doses of the LID/NIAID Live-Attenuated Tetravalent Dengue Vaccine, TV003, Administered Six Months Apart, to Healthy Adults, Adolescents, and Children in Thailand Completed NCT02332733 Phase 2
38 A Randomized, Double Blind, Phase 2 Study to Assess the Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Adults Completed NCT02193087 Phase 2 TDV Liquid Formulation 1;TDV Liquid Formulation 2;TDV IDT Lyophilized;Placebo
39 A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children Completed NCT00384670 Phase 1, Phase 2
40 A Phase I/II, Open, Five-year, Clinical Follow-up Study of Thai Children Who Participated in Dengue-003 ("A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus Antibody Naive Children") With Evaluation of a Booster Dose Given One Year After Primary DEN Vaccination Series Completed NCT01843621 Phase 1, Phase 2
41 A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants Completed NCT00322049 Phase 1, Phase 2
42 A Randomized Double Blind Placebo Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin (IVIG) in Children With Japanese Encephalitis in Nepal Completed NCT01856205 Phase 2 Intravenous immunoglobulin [ImmunoRel™ (batch 20081217)]
43 An Open-Label, Phase 2 Trial to Investigate the Humoral and Cell-Mediated Immune Responses and Safety of a Tetravalent Dengue Vaccine Candidate (TDV) Administered Subcutaneously in Flavivirus-Naïve and Dengue-Immune Healthy Adults Recruiting NCT03746015 Phase 2
44 Phase II, Randomized, Double-blind, Clinical Tial of the Safety and Immunogenicity of a Tetravalent Dengue Virus Vaccine Admixture TV005 in the Elderly Aged 50-70 Years in Taiwan Recruiting NCT04133987 Phase 2
45 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults Aged 18 to 50 Years in Brazil Recruiting NCT02741128 Phase 2
46 Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Immunogenicity of the Recombinant Live Attenuated Tetravalent Dengue Virus Vaccine Admixture TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh Active, not recruiting NCT02678455 Phase 2
47 Immunogenicity and Safety of Tetravalent Dengue Vaccine Given in 1 , 2 , or 3 Dose Schedules (STAGE I) Followed by a Single Booster Injection of the Same Vaccine (STAGE II) 1 or 2 Years After the Last Primary Dose in Healthy Subjects 9 to 50 Years of Age in Colombia and the Philippines Active, not recruiting NCT02628444 Phase 2
48 A Phase Ib/IIa Single Centre, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Dose Ranging Trial in Adult Participants With Uncomplicated Dengue Fever in Singapore Not yet recruiting NCT02569827 Phase 1, Phase 2 Celgosivir;Modipafant 50mg;Placebo;Modipafant 100mg
49 A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Safety, Pharmacokinetic, Pharmacodynamic and Preliminary Efficacy Study of IC14 in Adult Patients With Dengue Fever Withdrawn NCT03875560 Phase 2 Placebo
50 Phase I Study of the Safety and Immunogenicity of rDEN1delta30, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 1 Completed NCT00089908 Phase 1

Search NIH Clinical Center for Dengue Virus

Genetic Tests for Dengue Virus

Genetic tests related to Dengue Virus:

# Genetic test Affiliating Genes
1 Dengue Virus, Susceptibility to 29 CD209

Anatomical Context for Dengue Virus

MalaCards organs/tissues related to Dengue Virus:

40
T Cells, Testes, Endothelial, Liver, Monocytes, B Cells, Skin

Publications for Dengue Virus

Articles related to Dengue Virus:

(show top 50) (show all 8791)
# Title Authors PMID Year
1
A variant in the CD209 promoter is associated with severity of dengue disease. 61 56 6
15838506 2005
2
IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity. 61 56
28126818 2017
3
Dengue subgenomic RNA binds TRIM25 to inhibit interferon expression for epidemiological fitness. 61 56
26138103 2015
4
Dengue virus requires the CC-chemokine receptor CCR5 for replication and infection development. 61 56
25939314 2015
5
A molecular evaluation of dengue virus pathogenesis and its latest vaccine strategies. 61 56
21107723 2011
6
Dengue: a continuing global threat. 61 56
21079655 2010
7
Dengue virus nonstructural protein 3 redistributes fatty acid synthase to sites of viral replication and increases cellular fatty acid synthesis. 61 56
20855599 2010
8
Discovery of insect and human dengue virus host factors. 61 56
19396146 2009
9
CLEC5A is critical for dengue-virus-induced lethal disease. 61 56
18496526 2008
10
Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. 61 56
12783086 2003
11
Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MICB and PLCE1. 56
22001756 2011
12
The pathogenesis of dengue. 56
21781999 2011
13
Dengue hemorrhagic fever is associated with polymorphisms in JAK1. 56
20588308 2010
14
Promoter variation in the DC-SIGN-encoding gene CD209 is associated with tuberculosis. 6
16379498 2006
15
Association of DC-SIGN promoter polymorphism with increased risk for parenteral, but not mucosal, acquisition of human immunodeficiency virus type 1 infection. 6
15564514 2004
16
Simple production of hydrophobin-fused domain III of dengue envelope protein and induction of neutralizing antibodies against the homotypic serotype of dengue virus. 61
31828570 2020
17
Serological point-of-care and label-free capacitive diagnosis of dengue virus infection. 61
31999580 2020
18
Dengue virus envelope protein domain III-elicited antibodies mediate cross-protection against Zika virus in a mouse model. 61
31981774 2020
19
A synthetic peptide analog of in silico-predicted immunogenic epitope unique to dengue virus serotype 2 NS1 antigen specifically binds immunoglobulin G antibodies raised in rabbits. 61
31710119 2020
20
The establishment and clinical evaluation of a novel, rapid, no-wash one-step immunoassay for the detection of dengue virus non-structural protein 1. 61
31794781 2020
21
Small Molecule Inhibitor of ATPase Activity of HSP70 as a Broad-Spectrum Inhibitor against Flavivirus Infections. 61
31967789 2020
22
Altered m6A Modification of Specific Cellular Transcripts Affects Flaviviridae Infection. 61
31810760 2020
23
A Review on Dengue Vaccine Development. 61
32024238 2020
24
Efficient Synthesis of Muramic and Glucuronic Acid Glycodendrimers as Dengue Virus Antagonists. 61
31644824 2020
25
Suppression of µ1 subunit of the adaptor protein complex 2 reduces dengue virus release. 61
31720911 2020
26
Re-emergence of dengue virus serotype 3 infections in Gabon in 2016-2017, and evidence for the risk of repeated dengue virus infections. 61
31821892 2020
27
Successive blood meals enhance virus dissemination within mosquitoes and increase transmission potential. 61
31819213 2020
28
Impact of flavivirus vaccine-induced immunity on primary Zika virus antibody response in humans. 61
32017766 2020
29
Chemical composition and larvicidal activity against Aedes mosquitoes of essential oils from Arisaema fargesii. 61
31270930 2020
30
Benzenesulfonamide Derivatives as Calcium/Calmodulin-Dependent Protein Kinase Inhibitors and Antiviral Agents against Dengue and Zika Virus Infections. 61
31972088 2020
31
Prevalence of dengue antibodies in healthy children and adults in different Colombian endemic areas. 61
31733358 2020
32
SERS Platform for Dengue Diagnosis from Clinical Samples Employing a Hand Held Raman Spectrometer. 61
31909593 2020
33
Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor. 61
32015557 2020
34
Cephalotaxine inhibits Zika infection by impeding viral replication and stability. 61
31818462 2020
35
Opto-electrochemical functionality of Ru(II)-reinforced graphene oxide nanosheets for immunosensing of dengue virus non-structural 1 protein. 61
31757561 2020
36
Neopterin levels and Kyn/Trp ratios were significantly increased in dengue virus patients and subsequently decreased after recovery. 61
31821895 2020
37
Mechanism of differential Zika and dengue virus neutralization by a public antibody lineage targeting the DIII lateral ridge. 61
31757867 2020
38
Micronutrients, Immunological Parameters, and Dengue Virus Infection in Coastal Ecuador: A Nested Case-Control Study in an Infectious Disease Surveillance Program. 61
31428794 2020
39
Whole genome sequencing and genetic variations in several dengue virus type 1 strains from unusual dengue epidemic of 2017 in Vietnam. 61
31959201 2020
40
The detection of anti-dengue virus IgM in urine in participants enrolled in an acute febrile illness study in Puerto Rico. 61
31995560 2020
41
Two Cases of Dengue Virus Type 2 (DENV-2) Infection in a Japanese Couple Returning from the Maldives during the 2018 Dengue Outbreak. 61
31474701 2020
42
A genome-wide CRISPR-Cas9 screen identifies the dolichol-phosphate mannose synthase complex as a host dependency factor for dengue virus infection. 61
31915280 2020
43
Effect of high doses of vitamin D supplementation on dengue virus replication, Toll-like receptor expression, and cytokine profiles on dendritic cells. 61
31758375 2020
44
Molecular Detection of Dengue Virus in Mosquitoes as an Early Indicator to Aid in the Prevention of Human Infection in Endemic Areas. 61
31697613 2020
45
Structure-activity relationship study of the pyridine moiety of isothiazolo[4,3-b]pyridines as antiviral agents targeting cyclin G-associated kinase. 61
31757682 2020
46
Integrated Early Warning Surveillance: Achilles' Heel of One Health? 61
31936412 2020
47
RK-33 Is a Broad-Spectrum Antiviral Agent That Targets DEAD-Box RNA Helicase DDX3X. 61
31936642 2020
48
Profiling of flaviviral NS2B-NS3 protease specificity provides a structural basis for the development of selective chemical tools that differentiate Dengue from Zika and West Nile viruses. 61
32014497 2020
49
Structure and function of cis-acting RNA elements of flavivirus. 61
31777997 2020
50
Labyrinthopeptins Exert Broad-Spectrum Antiviral Activity through Lipid-Binding-Mediated Virolysis. 61
31666384 2020

Variations for Dengue Virus

ClinVar genetic disease variations for Dengue Virus:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CD209 CD209, -336A-GSNV protective,risk factor 5408

Expression for Dengue Virus

Search GEO for disease gene expression data for Dengue Virus.

Pathways for Dengue Virus

GO Terms for Dengue Virus

Cellular components related to Dengue Virus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.4 STAT2 RPSA OAS3 MRC1 IFITM3 IFITM2

Biological processes related to Dengue Virus according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 10.06 RSAD2 OAS3 IFITM3 IFITM2 IFITM1 IFIH1
2 immune system process GO:0002376 10.04 RSAD2 OAS3 IFITM1 IFIH1 DDX58 CLEC5A
3 viral entry into host cell GO:0046718 9.85 RPSA MRC1 HAVCR1 CLEC5A CLDN1 CD209
4 type I interferon signaling pathway GO:0060337 9.8 STAT2 RSAD2 OAS3 IFITM3 IFITM2 IFITM1
5 response to virus GO:0009615 9.8 RSAD2 OAS3 IFITM3 IFITM2 IFITM1 IFIH1
6 cellular response to interferon-gamma GO:0071346 9.78 MRC1 LGALS9 CLDN1
7 response to interferon-gamma GO:0034341 9.76 SHFL IFITM3 IFITM2 IFITM1
8 response to interferon-beta GO:0035456 9.73 SHFL IFITM3 IFITM2 IFITM1
9 positive regulation of interleukin-6 secretion GO:2000778 9.72 LGALS9 IFIH1 DDX58
10 positive regulation of tumor necrosis factor secretion GO:1904469 9.7 LGALS9 IFIH1 DDX58
11 viral process GO:0016032 9.7 STAT2 RSAD2 RPSA MRC1 IFIH1 HAVCR1
12 negative regulation of viral entry into host cell GO:0046597 9.69 IFITM3 IFITM2 IFITM1
13 response to interferon-alpha GO:0035455 9.65 IFITM3 IFITM2 IFITM1
14 negative regulation of viral genome replication GO:0045071 9.63 SHFL RSAD2 OAS3 IFITM3 IFITM2 IFITM1
15 negative regulation of type I interferon production GO:0032480 9.62 IFIH1 DDX58
16 positive regulation of interferon-beta production GO:0032728 9.62 IFIH1 DDX58
17 cellular response to exogenous dsRNA GO:0071360 9.61 IFIH1 DDX58
18 positive regulation of interferon-alpha production GO:0032727 9.6 IFIH1 DDX58
19 positive regulation of interferon-alpha secretion GO:1902741 9.59 IFIH1 DDX58
20 positive regulation of response to cytokine stimulus GO:0060760 9.58 IFIH1 DDX58
21 detection of virus GO:0009597 9.58 IFIH1 DDX58
22 positive regulation of interferon-beta secretion GO:0035549 9.57 IFIH1 DDX58
23 cytoplasmic pattern recognition receptor signaling pathway in response to virus GO:0039528 9.56 IFIH1 DDX58
24 regulation of type III interferon production GO:0034344 9.54 IFIH1 DDX58
25 defense response to virus GO:0051607 9.32 STAT2 SHFL RSAD2 OAS3 IFITM3 IFITM2

Molecular functions related to Dengue Virus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 double-stranded RNA binding GO:0003725 9.33 OAS3 IFIH1 DDX58
2 mannose binding GO:0005537 9.26 MRC1 CD209
3 carbohydrate binding GO:0030246 9.26 MRC1 LGALS9 CLEC5A CD209
4 virus receptor activity GO:0001618 9.1 RPSA MRC1 HAVCR1 CLEC5A CLDN1 CD209

Sources for Dengue Virus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....